ClinicalTrials.gg
TerminatedNCT03297294EMPADINEUpdated Oct 8, 2021Results posted

Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)

A Phase 2 interventional study of EMA401 and Placebo in Painful Diabetic Neuropathy, sponsored by Novartis Pharmaceuticals. Terminated at 64 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-08.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Why this study was terminated
Study was terminated due to animal toxicity data

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate safety and efficacy of EMA401 compared to placebo in patients with painful diabetic neuropathy (PDN).

Read the detailed description

This was an interventional, randomized, parallel, placebo-controlled, double-blind treatment study consisting of 3 periods i.e. Screening, Treatment, and Treatment withdrawal. Patients were planned to be randomized in a 1:1 ratio to Placebo b.i.d. or EMA401 100 mg b.i.d.. Concomitant use of pregabalin or duloxetine at stable doses was allowed. Based on historical data, it was planned that the study would enroll approximately 50% of patients who were on stable doses of concomitant pregabalin or duloxetine in the study. At the end of treatment period the 100mg b.i.d. arm was re-randomized (1:1) to the same treatment or placebo. Placebo arm stayed on placebo. The planned duration of treatment period was 12 weeks and 1 week of treatment withdrawal at the end of treatment period.

The study was terminated early due to pre-clinical toxicity data that became available after start of trial. Novartis implemented a Urgent Safety Measure (USM) which instructed sites to discontinue study treatment immediately and to have all patients return for additional laboratory assessments (full hematology including coagulation and clinical chemistry panel). Safety data from the USM was presented as a separate outcome measure table and not included in the Adverse Event section

02

Conditions studied

  • Painful Diabetic Neuropathy

Keywords

  • Painful diabetic neuropathy
  • Neuropathic pain
  • Angiotensin II type 2 receptor antagonist
  • adult
  • EMA401
  • diabetic neuropathy
03

In context

Diabetic Neuropathies

539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.

This study's enrollment of 142 is above the median of 68 across 449 interventional studies indexed under Diabetic Neuropathies.

Browse Diabetic Neuropathies studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.

Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At the time of Screening, must have had documented diagnosis of Type I OR Type II diabetes mellitus (DM) with painful distal symmetrical sensorimotor neuropathy (ICD-10 code G63.2) of more than 6 months duration with any one or more of the following:

    • Neuropathic symptoms (e.g. numbness, non-painful paresthesias or tingling, non-painful sensory distortions or misinterpretations, etc.)
    • Decreased distal sensation (e.g. decreased vibration, pinprick sensation, light touch, etc.)
  • Been assessed as suffering from moderate to severe neuropathic pain across the Screening epoch (NRS ≥ 4).
  • A score of ≥4 on the Douleur Neuropathique en 4 Questions (DN4) questionnaire at Screening.

Exclusion criteria

Exclusion Criteria:

  • Women of , defined as all women physiologically capable of becoming pregnant, unless they were using highly effective methods of during dosing and for 3 days after stopping of study medication. Highly effective contraception methods included:

    • Total abstinence (when this was is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal were not acceptable methods of contraception.
    • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks before taking drug. In case of oophorectomy alone, only when the reproductive status of the woman had been confirmed by follow up hormone level assessment.
    • Male sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should have been the sole partner for that subject.
    • Placement of an intrauterine device (IUD) or intrauterine system (IUS).
  • History or current diagnosis of (ECG) abnormalities indicating significant risk of safety for patients participating in the study.
  • Major depressive episode within 6 months prior to Screening and/or a history of diagnosed recurrent major depressive disorder according to , 5th Edition (DSM-V) diagnostic criteria.
  • Had evidence of significant renal insufficiency or pre-existing liver condition.
  • Had ≤ 100 x 10\^9/L, or \< 1.2 x 10\^9/L (or equivalent), ≤ 100 g/L for women or hemoglobin ≤ 110 g/L for men.
  • Participants whose glycemic control had been unstable within 3 months immediately prior to screening (e.g., ketoacidosis requiring hospitalization, any recent episode of hypoglycemia requiring assistance through medical intervention, uncontrolled hyperglycemia)
  • Patients who had any differential diagnosis of PDN including but not limited to other neuropathies (e.g. Vitamin B12 deficiency, Chronic Inflammatory Demyelinating Polyneuropathy), polyradiculopathies, central disorders (e.g. demyelinating disease), or rheumatological disease (e.g., foot arthritis, plantar fasciitis).
  • Patient was unwilling or unable to complete daily eDiary.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    EMA401

    During the treatment epoch, patients will receive EMA401 for 12 weeks. During the treatment withdrawal epoch, patients will receive EMA401 or matching placebo for 1 week.

    Drug: EMA401 · Drug: Placebo

  • Placebo comparator
    Placebo

    Participants will receive matching placebo to EMA401 during both the treatment and treatment withdrawal epochs for a total of 13 weeks.

    Drug: Placebo

Interventions

  • DrugEMA401

    capsules, oral

  • DrugPlacebo

    Placebo to EMA401 capsules, oral

06

What researchers measure

Primary outcomes

  1. Change in Weekly Mean 24-hour Average Pain Score Using the 11 Point Numerical Rating Scale (NRS) From Baseline to Week 12

    The NRS is an 11-point scale ranging from zero ("no pain") to ten ("pain as bad as you can imagine") for self-reporting of pain by patients. The following parameters were evaluated using the 11-point NRS: 24-hour Average Pain Score and 24-hour Worst Pain Score Patients evaluated their "average pain" and "worst pain" during the past 24 hours in the evening prior to sleep by touching the appropriate corresponding number between zero and ten on a eDiary device.

    Time frame: Baseline up to Week 12

Secondary outcomes

  1. Change in Neuropathic Pain Symptom Inventory (NPSI) From Baseline to Week 12

    The Neuropathic Pain Symptom Inventory (NPSI) is a 12 item patient reported outcome measure that contains 10 descriptors representing 5 dimensions of pain (burning pain, deep/pressing pain, paroxysmal pain, evoked pain and paraesthesia/dysesthesia) and 2 temporal items designed to assess pain duration and the number of pain paroxysms. The sum of the responses to the 10 questions (all except temporal questions) was regarded as the total score and was divided by 10 (10 questions). The range of the total score and of the 5 dimensional scores is 0 to 10. Lower values represent better outcomes.

    Time frame: Baseline up to Week 12

  2. Change in Brief Pain Inventory-Short Form Interference (BPI-SF) Mean Total Score From Baseline to Week 12

    The BPI-SF is a validated, self-administered (at clinic) questionnaire that assesses pain severity and its mpact on daily functions. Patients were asked to complete the 7-item pain interference scale that assessed the degree to which pain interfered with walking and other physical activity, work, mood, relations with others and sleep using a zero to ten scale with zero being "does not interfere" and ten being "completely interferes". The BPI total score is the sum of the 7 items. Each item ranges from 0 to 10, thus the total score ranges from 0 to 70. Lower values indicate a better outcome.

    Time frame: Baseline up to Week 12

  3. Change in Weekly Mean of the 24-hour Worst Pain Score, Using an 11-point NRS, From Baseline to Week 12

    The NRS is an 11-point scale ranging from zero ("no pain") to ten ("pain as bad as you can imagine") for self-reporting of pain by patients. The following parameters were evaluated using the 11-point NRS: 24-hour Average Pain Score and 24-hour Worst Pain Score Patients evaluated their "average pain" and "worst pain" during the past 24 hours in the evening prior to sleep by touching the appropriate corresponding number between zero and ten on a eDiary device.

    Time frame: Baseline up to Week 12

  4. Number of Participants Per Patient Global Impression of Change Category at Week 12

    The Patient Global Impression of Change (PGIC) is a patient-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse"). The PGIC is based on the validated Clinical Global Impression of Change scale. The PGIC was to be completed by patients using the electronic tablet at the site

    Time frame: Baseline up to Week 12

  5. Percentage of Patients Achieving at Least 30% Pain Reduction at Week 12 on NRS 11 Point Scale

    The NRS is an 11-point scale ranging from zero ("no pain") to ten ("pain as bad as you can imagine") for self-reporting of pain by patients. The number of patients with observed response, i.e. a decrease of 30% units in weekly mean of the 24-hour average pain score NRS. Logistic regression model with region, treatment, sex, use of PHN medications (yes/no) as factors and age and baseline NRS as covariates. An odds ratio \>1 = higher chance of a clinically important improvement.

    Time frame: Baseline up to Week 12

  6. Percentage of Patients Achieving at Least 50% Pain Reduction at Week 12 on NRS 11 Point Scale

    The NRS is an 11-point scale ranging from zero ("no pain") to ten ("pain as bad as you can imagine") for self-reporting of pain by patients. The number of patients with observed response, i.e. a decrease of 50% units in weekly mean of the 24-hour average pain score NRS. Logistic regression model with region, treatment, sex, use of PHN medications (yes/no) as factors and age and baseline NRS as covariates. An odds ratio \>1 = higher chance of a clinically important improvement.

    Time frame: Baseline up to Week 12

  7. Mean Change in Insomnia Severity Index (ISI) From Baseline to Week 12

    Patients were asked to complete the ISI using five-point Likert-style scale as a measure of perceived sleep difficulties. The questionnaire assessed the severity of insomnia, satisfaction with current sleep pattern, sleep interference, "noticeability" of sleeping problem to others and concern about sleeping problems. The scale consists of 7 items. The sum of seven items represents the total score. Each of the 7 items is scored using a range from 0 to 4, thus the total score values ranges from zero to 28. Lower values represent better outcomes.

    Time frame: Baseline up to Week 12

  8. Plasma Pharmacokinetics (PK) Concentrations at Week 8 and 12

    Due to the premature termination of the study, the number of patients and observations providing PK data was much smaller than planned, and no PK model was developed. As a consequence, no PK parameters (Cmax, Tmax, AUC) were derived for this study. Only, summary statistics of the plasma concentrations were calculated

    Time frame: Week 8 (Prior dose, 1-3 hours, 4-6 hours), Week 12 (Prior dose, 1-3 hours, 4-6 hours)

  9. Percentage of Patients Who Required Rescue Medication in Double-blind Treatment Period

    Patients were allowed to take acetaminophen/paracetamol up to a maximum of 3 g daily (divided into 4 times/day) for unacceptable pain due to any reason during the study. This medication use was to be recorded in eDiary prior to use. Percentages of patients presented are those who required rescue meds within 7 days prior to visit.

    Time frame: Baseline and weekly up to 12 weeks, once during double-blind period

  10. Percentage of Patients Who Required Rescue Medication in Treatment Withdrawal Period

    Patients were allowed to take acetaminophen/paracetamol up to a maximum of 3 g daily (divided into 4 times/day) for unacceptable pain due to any reason during the study. This medication use was to be recorded in eDiary prior to use. Percentages of patients presented are those who required rescue meds within 7 days prior to visit.

    Time frame: Week 12 to Week 13 (planned duration subject to varibility in visit scheduling)

  11. Time to First Rescue Medication Intake

    Patients were allowed to take acetaminophen/paracetamol up to a maximum of 3 g daily (divided into 4 times/day) for unacceptable pain due to any reason during the study. This medication use was to be recorded in eDiary prior to use. Patients who did not take any rescue medication were censored at the last date of double-blind treatment period.

    Time frame: Baseline up to day 92

  12. Treatment Emergent Adverse Events During Urgent Safety Measure (USM) Follow-Up

    Participants were instructed to stop taking drug immediately upon termination of study and asked to come in for two unscheduled visits for follow up safety assessments

    Time frame: Approximately from 3 weeks after end of study up to 16 weeks

07

Results

Posted Jun 4, 2020

Participant flow

Double-Blind Treatment Period (DB)
Participant flow — Double-Blind Treatment Period (DB)
MilestoneEMA401 100mg BID DBPlacebo BID DBEMA401 100mg BID -> EMA401 100mg BID TWEMA401 100mg BID -> Placebo BID TWPlacebo BID -> Placebo BID TW
Started7067000
Completed3230000
Not completed3837000
Withdrew: Study terminated by sponsor3031000
Withdrew: Withdrawal by subject44000
Withdrew: Adverse event31000
Withdrew: Physician decision11000
Treatment Withdrawal Period (TW)
Participant flow — Treatment Withdrawal Period (TW)
MilestoneEMA401 100mg BID DBPlacebo BID DBEMA401 100mg BID -> EMA401 100mg BID TWEMA401 100mg BID -> Placebo BID TWPlacebo BID -> Placebo BID TW
Started00141227
Completed00141127
Not completed00010
Withdrew: Study terminated by sponsor00010

Outcome measures

PrimaryChange in Weekly Mean 24-hour Average Pain Score Using the 11 Point Numerical Rating Scale (NRS) From Baseline to Week 12

The NRS is an 11-point scale ranging from zero ("no pain") to ten ("pain as bad as you can imagine") for self-reporting of pain by patients. The following parameters were evaluated using the 11-point NRS: 24-hour Average Pain Score and 24-hour Worst Pain Score Patients evaluated their "average pain" and "worst pain" during the past 24 hours in the evening prior to sleep by touching the appropriate corresponding number between zero and ten on a eDiary device.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · scores on a scale
Change in Weekly Mean 24-hour Average Pain Score Using the 11 Point Numerical Rating Scale (NRS) From Baseline to Week 12
scores on a scaleEMA401 100mg BID DBPlacebo BID DB
Week 4-1.0 ± 0.21-0.8 ± 0.18
Week 8-1.7 ± 0.29-1.1 ± 0.26
Week 12-1.9 ± 0.31-1.3 ± 0.27
Statistical analysis
  • EMA401 100mg BID DB vs Placebo BID DB · ANCOVA · p = 0.101 · Least squares mean: -0.6 · 95% CI -1.4 to 0.1
SecondaryChange in Neuropathic Pain Symptom Inventory (NPSI) From Baseline to Week 12

The Neuropathic Pain Symptom Inventory (NPSI) is a 12 item patient reported outcome measure that contains 10 descriptors representing 5 dimensions of pain (burning pain, deep/pressing pain, paroxysmal pain, evoked pain and paraesthesia/dysesthesia) and 2 temporal items designed to assess pain duration and the number of pain paroxysms. The sum of the responses to the 10 questions (all except temporal questions) was regarded as the total score and was divided by 10 (10 questions). The range of the total score and of the 5 dimensional scores is 0 to 10. Lower values represent better outcomes.

Time frame:
Baseline up to Week 12
Reported as:
Least squares mean · scores on a scale
Change in Neuropathic Pain Symptom Inventory (NPSI) From Baseline to Week 12
scores on a scaleEMA401 100mg BID DBPlacebo BID DB
Week 4-1.2 ± 0.19-1.0 ± 0.18
Week 8-1.3 ± 0.25-0.9 ± 0.22
Week 12-1.6 ± 0.32-1.1 ± 0.26
Statistical analysis
  • EMA401 100mg BID DB vs Placebo BID DB · ANCOVA · p = 0.168 · Ls mean difference: -0.5 · 95% CI -1.3 to 0.2
SecondaryChange in Brief Pain Inventory-Short Form Interference (BPI-SF) Mean Total Score From Baseline to Week 12

The BPI-SF is a validated, self-administered (at clinic) questionnaire that assesses pain severity and its mpact on daily functions. Patients were asked to complete the 7-item pain interference scale that assessed the degree to which pain interfered with walking and other physical activity, work, mood, relations with others and sleep using a zero to ten scale with zero being "does not interfere" and ten being "completely interferes". The BPI total score is the sum of the 7 items. Each item ranges from 0 to 10, thus the total score ranges from 0 to 70. Lower values indicate a better outcome.

Time frame:
Baseline up to Week 12
Reported as:
Mean · scores on a scale
Change in Brief Pain Inventory-Short Form Interference (BPI-SF) Mean Total Score From Baseline to Week 12
scores on a scaleEMA401 100mg BID DBPlacebo BID DB
Change in Brief Pain Inventory-Short Form Interference (BPI-SF) Mean Total Score From Baseline to Week 12-12.03 ± 13.336-10.83 ± 14.602
SecondaryChange in Weekly Mean of the 24-hour Worst Pain Score, Using an 11-point NRS, From Baseline to Week 12

The NRS is an 11-point scale ranging from zero ("no pain") to ten ("pain as bad as you can imagine") for self-reporting of pain by patients. The following parameters were evaluated using the 11-point NRS: 24-hour Average Pain Score and 24-hour Worst Pain Score Patients evaluated their "average pain" and "worst pain" during the past 24 hours in the evening prior to sleep by touching the appropriate corresponding number between zero and ten on a eDiary device.

Time frame:
Baseline up to Week 12
Reported as:
Mean · scores on numeric rating scale
Change in Weekly Mean of the 24-hour Worst Pain Score, Using an 11-point NRS, From Baseline to Week 12
scores on numeric rating scaleEMA401 100mg BID DBPlacebo BID DB
Change in Weekly Mean of the 24-hour Worst Pain Score, Using an 11-point NRS, From Baseline to Week 12-1.63 ± 1.837-1.28 ± 1.577
SecondaryNumber of Participants Per Patient Global Impression of Change Category at Week 12

The Patient Global Impression of Change (PGIC) is a patient-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse"). The PGIC is based on the validated Clinical Global Impression of Change scale. The PGIC was to be completed by patients using the electronic tablet at the site

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
Number of Participants Per Patient Global Impression of Change Category at Week 12
ParticipantsEMA401 100mg BID DBPlacebo BID DB
Very much improved42
Much improved711
Minimally improved1718
No change1814
Minimally worse32
Much worse00
Very much worse00
Missing2120
SecondaryPercentage of Patients Achieving at Least 30% Pain Reduction at Week 12 on NRS 11 Point Scale

The NRS is an 11-point scale ranging from zero ("no pain") to ten ("pain as bad as you can imagine") for self-reporting of pain by patients. The number of patients with observed response, i.e. a decrease of 30% units in weekly mean of the 24-hour average pain score NRS. Logistic regression model with region, treatment, sex, use of PHN medications (yes/no) as factors and age and baseline NRS as covariates. An odds ratio \>1 = higher chance of a clinically important improvement.

Time frame:
Baseline up to Week 12
Reported as:
Number · % of participants - model adjusted rate
Percentage of Patients Achieving at Least 30% Pain Reduction at Week 12 on NRS 11 Point Scale
% of participants - model adjusted rateEMA401 100mg BID DBPlacebo BID DB
Week 4 - at least 30% pain reduction34.024.7
Week 12 - at least 30% pain reduction52.740.4
Statistical analysis
  • EMA401 100mg BID DB vs Placebo BID DB · Regression, Logistic · p = 0.255 · Odds ratio (or): 1.6 · 95% CI 0.7 to 3.9
SecondaryPercentage of Patients Achieving at Least 50% Pain Reduction at Week 12 on NRS 11 Point Scale

The NRS is an 11-point scale ranging from zero ("no pain") to ten ("pain as bad as you can imagine") for self-reporting of pain by patients. The number of patients with observed response, i.e. a decrease of 50% units in weekly mean of the 24-hour average pain score NRS. Logistic regression model with region, treatment, sex, use of PHN medications (yes/no) as factors and age and baseline NRS as covariates. An odds ratio \>1 = higher chance of a clinically important improvement.

Time frame:
Baseline up to Week 12
Reported as:
Number · % of participants - model adjusted rate
Percentage of Patients Achieving at Least 50% Pain Reduction at Week 12 on NRS 11 Point Scale
% of participants - model adjusted rateEMA401 100mg BID DBPlacebo BID DB
Percentage of Patients Achieving at Least 50% Pain Reduction at Week 12 on NRS 11 Point Scale31.414.1
Statistical analysis
  • EMA401 100mg BID DB vs Placebo BID DB · Regression, Logistic · p = 0.100 · Odds ratio (or): 2.8 · 95% CI 0.8 to 9.6
SecondaryMean Change in Insomnia Severity Index (ISI) From Baseline to Week 12

Patients were asked to complete the ISI using five-point Likert-style scale as a measure of perceived sleep difficulties. The questionnaire assessed the severity of insomnia, satisfaction with current sleep pattern, sleep interference, "noticeability" of sleeping problem to others and concern about sleeping problems. The scale consists of 7 items. The sum of seven items represents the total score. Each of the 7 items is scored using a range from 0 to 4, thus the total score values ranges from zero to 28. Lower values represent better outcomes.

Time frame:
Baseline up to Week 12
Reported as:
Mean · scores on a scale
Mean Change in Insomnia Severity Index (ISI) From Baseline to Week 12
scores on a scaleEMA401 100mg BID DBPlacebo BID DB
Mean Change in Insomnia Severity Index (ISI) From Baseline to Week 12-4.00 ± 4.854-1.03 ± 6.312
SecondaryPlasma Pharmacokinetics (PK) Concentrations at Week 8 and 12

Due to the premature termination of the study, the number of patients and observations providing PK data was much smaller than planned, and no PK model was developed. As a consequence, no PK parameters (Cmax, Tmax, AUC) were derived for this study. Only, summary statistics of the plasma concentrations were calculated

Time frame:
Week 8 (Prior dose, 1-3 hours, 4-6 hours), Week 12 (Prior dose, 1-3 hours, 4-6 hours)
Reported as:
Geometric mean · ng/mL
Plasma Pharmacokinetics (PK) Concentrations at Week 8 and 12
ng/mLEMA401 100mg BID DB
Week 8 Prior dose30.5 ± 126.6
Week 8 1-3 hours205.1 ± 212.8
Week 8 4-6 hours72.8 ± 115.2
Week 12 Prior dose29.5 ± 209.3
Week 12 1-3 hours118.4 ± 278.3
Week 12 4-6 hours89.8 ± 117.0
SecondaryPercentage of Patients Who Required Rescue Medication in Double-blind Treatment Period

Patients were allowed to take acetaminophen/paracetamol up to a maximum of 3 g daily (divided into 4 times/day) for unacceptable pain due to any reason during the study. This medication use was to be recorded in eDiary prior to use. Percentages of patients presented are those who required rescue meds within 7 days prior to visit.

Time frame:
Baseline and weekly up to 12 weeks, once during double-blind period
Reported as:
Number · Percentage of participants
Percentage of Patients Who Required Rescue Medication in Double-blind Treatment Period
Percentage of participantsEMA401 100mg BID DBPlacebo BID DB
Week 113.010.6
Week 27.79.5
Week 48.67.0
Week 67.87.5
Week 89.39.5
Week 105.313.2
Week 122.98.6
At least once during double-blind period20.019.4
SecondaryPercentage of Patients Who Required Rescue Medication in Treatment Withdrawal Period

Patients were allowed to take acetaminophen/paracetamol up to a maximum of 3 g daily (divided into 4 times/day) for unacceptable pain due to any reason during the study. This medication use was to be recorded in eDiary prior to use. Percentages of patients presented are those who required rescue meds within 7 days prior to visit.

Time frame:
Week 12 to Week 13 (planned duration subject to varibility in visit scheduling)
Reported as:
Number · Percentage of participants
Percentage of Patients Who Required Rescue Medication in Treatment Withdrawal Period
Percentage of participantsEMA401 100mg BID -> EMA401 100mg BID TWEMA401 100mg BID -> Placebo BID TWPlacebo BID -> Placebo BID TW
Percentage of Patients Who Required Rescue Medication in Treatment Withdrawal Period14.38.37.4
SecondaryTime to First Rescue Medication Intake

Patients were allowed to take acetaminophen/paracetamol up to a maximum of 3 g daily (divided into 4 times/day) for unacceptable pain due to any reason during the study. This medication use was to be recorded in eDiary prior to use. Patients who did not take any rescue medication were censored at the last date of double-blind treatment period.

Time frame:
Baseline up to day 92
Reported as:
Median · days
Time to First Rescue Medication Intake
daysEMA401 100mg BID DBPlacebo BID DB
Time to First Rescue Medication Intake44.0 (2 to 90)56.5 (2 to 92)
SecondaryTreatment Emergent Adverse Events During Urgent Safety Measure (USM) Follow-Up

Participants were instructed to stop taking drug immediately upon termination of study and asked to come in for two unscheduled visits for follow up safety assessments

Time frame:
Approximately from 3 weeks after end of study up to 16 weeks
Reported as:
Count of participants · Participants
Treatment Emergent Adverse Events During Urgent Safety Measure (USM) Follow-Up
ParticipantsEMA401 100mg BID -> EMA401 100mg BID TWEMA401 100mg BID -> Placebo BID TWPlacebo BID -> Placebo BID TW
Peritoneal adhesions100
Cholelithiasis100
Liver abscess100
Blood creatinine increased001

Adverse events

Collected over Adverse events were collected from first dose of study treatment until end of study treatment plus 21 days post treatment, up to maximum duration of 111 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EMA401 100mg BID DB0/69 (0%)5/69 (7.2%)23/69 (33.3%)
Placebo BID DB0/66 (0%)3/66 (4.5%)10/66 (15.2%)
EMA401 100mg BID -> EMA401 100mg BID TW0/14 (0%)0/14 (0%)1/14 (7.1%)
EMA401 100mg BID -> Placebo BID TW0/12 (0%)0/12 (0%)2/12 (16.7%)
Placebo BID -> Placebo BID TW0/26 (0%)0/26 (0%)0/26 (0%)
Most frequent serious events
Most frequent serious events
EventEMA401 100mg BID DBPlacebo BID DBEMA401 100mg BID -> EMA401 100mg BID TWEMA401 100mg BID -> Placebo BID TWPlacebo BID -> Placebo BID TW
Cholecystitis acuteHepatobiliary disorders2/690/660/140/120/26
Acute coronary syndromeCardiac disorders0/691/660/140/120/26
ErysipelasInfections and infestations0/691/660/140/120/26
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/691/660/140/120/26
Product intoleranceGeneral disorders1/690/660/140/120/26
CholelithiasisHepatobiliary disorders1/690/660/140/120/26
Localised infectionInfections and infestations1/690/660/140/120/26
Most frequent other events
Most frequent other events
EventEMA401 100mg BID DBPlacebo BID DBEMA401 100mg BID -> EMA401 100mg BID TWEMA401 100mg BID -> Placebo BID TWPlacebo BID -> Placebo BID TW
NasopharyngitisInfections and infestations4/696/660/140/120/26
Lipase increasedInvestigations6/690/661/140/120/26
PalpitationsCardiac disorders0/691/660/141/120/26
HypertensionVascular disorders1/692/660/141/120/26
Abdominal pain upperGastrointestinal disorders5/690/660/140/120/26
HeadacheNervous system disorders4/694/660/140/120/26
NauseaGastrointestinal disorders4/691/660/140/120/26
Gamma-glutamyltransferase increasedInvestigations4/691/660/140/120/26

Baseline characteristics

Age, Customized
Age, Customized(Participants)EMA401 100mg BID DBPlacebo BID DBTotal
18 - 64 years343367
65 - 84 years363369
≥ 85 years011
Sex: Female, Male
Sex: Female, Male(Participants)EMA401 100mg BID DBPlacebo BID DBTotal
Female202444
Male504393
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EMA401 100mg BID DBPlacebo BID DBTotal
Caucasian7063133
Asian011
Other033
Body mass index
Body mass index(kg/m^2)EMA401 100mg BID DBPlacebo BID DBTotal
Median30.8 (22.7 to 43.2)30.2 (19.5 to 48.2)30.6 (19.5 to 48.2)
08

Study locations

64 sites
  • Novartis Investigative Site
    Broadmeadow, New South Wales 2292, Australia
  • Novartis Investigative Site
    Orange, New South Wales 2800, Australia
  • Novartis Investigative Site
    Adelaide, South Australia 5000, Australia
  • Novartis Investigative Site
    Heidelberg Heights, Victoria 3081, Australia
  • Novartis Investigative Site
    Graz, A-8036, Austria
  • Novartis Investigative Site
    Klagenfurt, 9020, Austria
  • Novartis Investigative Site
    Wien, A-1090, Austria
  • Novartis Investigative Site
    Edegem, 2650, Belgium
  • Novartis Investigative Site
    Liege, 4000, Belgium
  • Novartis Investigative Site
    Pellenberg, 3212, Belgium
  • Novartis Investigative Site
    Sofia, Sofia-Grad 1336, Bulgaria
  • Novartis Investigative Site
    Sofia, 1000, Bulgaria
  • Novartis Investigative Site
    Sofia, 1407, Bulgaria
  • Novartis Investigative Site
    Sofia, 1431, Bulgaria
  • Novartis Investigative Site
    Ontario, CAN L4J 1W3, Canada
  • Novartis Investigative Site
    Thornhill, Ontario L4J 8L7, Canada
  • Novartis Investigative Site
    Toronto, Ontario M4G 3E8, Canada
  • Novartis Investigative Site
    Laval, Quebec H7T 2P5, Canada
  • Novartis Investigative Site
    Aarhus, 8000, Denmark
  • Novartis Investigative Site
    Gentofte, DK 2820, Denmark
  • Novartis Investigative Site
    Odense C, DK 5000, Denmark
  • Novartis Investigative Site
    Tampere, FIN-33520, Finland
  • Novartis Investigative Site
    Boulogne Billancourt, 92104, France
  • Novartis Investigative Site
    Bielefeld, D 33647, Germany
  • Novartis Investigative Site
    Duesseldorf, 40225, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Halle (Saale), 06120, Germany
  • Novartis Investigative Site
    Kassel, Germany
  • Novartis Investigative Site
    Kiel, 24119, Germany
  • Novartis Investigative Site
    Leipzig, 04109, Germany
  • Novartis Investigative Site
    Wiesbaden, 65191, Germany
  • Novartis Investigative Site
    Debrecen, HUN 4032, Hungary
  • Novartis Investigative Site
    Esztergom, HUN 2500, Hungary
  • Novartis Investigative Site
    Szeged, HUN 6720, Hungary
  • Novartis Investigative Site
    Balatonfured, 8230, Hungary
  • Novartis Investigative Site
    Budapest, 1085, Hungary
  • Novartis Investigative Site
    Budapest, 1089, Hungary
  • Novartis Investigative Site
    Kistarcsa, 2143, Hungary
  • Novartis Investigative Site
    Pecs, 7632, Hungary
  • Novartis Investigative Site
    Szeged, 6725, Hungary
  • Novartis Investigative Site
    Oslo, 0450, Norway
  • Novartis Investigative Site
    Krakow, POL 31 505, Poland
  • Novartis Investigative Site
    Bialystok, 15-351, Poland
  • Novartis Investigative Site
    Warszawa, 00 144, Poland
  • Novartis Investigative Site
    Caldas da Rainha, 2500 176, Portugal
  • Novartis Investigative Site
    Lisboa, 1250 203, Portugal
  • Novartis Investigative Site
    Matosinhos, 4454 509, Portugal
  • Novartis Investigative Site
    Porto, 4200 319, Portugal
  • Novartis Investigative Site
    Viana do Castelo, 4901858, Portugal
  • Novartis Investigative Site
    Vila Nova de Gaia, 4434 502, Portugal
  • Novartis Investigative Site
    Lucenec, Slovak Republic 98401, Slovakia
  • Novartis Investigative Site
    Bratislava, 83305, Slovakia
  • Novartis Investigative Site
    Bratislava, 85101, Slovakia
  • Novartis Investigative Site
    Presov, 080 01, Slovakia
  • Novartis Investigative Site
    Presov, 08001, Slovakia
  • Novartis Investigative Site
    Sevilla, Andalucia 41014, Spain
  • Novartis Investigative Site
    Madrid, 28222, Spain
  • Novartis Investigative Site
    Bradford, West Yorkshire BD9 6RJ, United Kingdom
  • Novartis Investigative Site
    Bath, BA1 3NG, United Kingdom
  • Novartis Investigative Site
    Bournemouth, BH7 7DW, United Kingdom
  • Novartis Investigative Site
    Edinburgh, EH4 2XU, United Kingdom
  • Novartis Investigative Site
    London, SE1 7EH, United Kingdom
  • Novartis Investigative Site
    Middlesborough, TS4 3BW, United Kingdom
  • Novartis Investigative Site
    Oldham, OL1 2JH, United Kingdom
09

References and documents

Publications

  • Rice ASC, Dworkin RH, Finnerup NB, Attal N, Anand P, Freeman R, Piaia A, Callegari F, Doerr C, Mondal S, Narayanan N, Ecochard L, Flossbach Y, Pandhi S. Efficacy and safety of EMA401 in peripheral neuropathic pain: results of 2 randomised, double-blind, phase 2 studies in patients with postherpetic neuralgia and painful diabetic neuropathy. Pain. 2021 Oct 1;162(10):2578-2589. doi: 10.1097/j.pain.0000000000002252. PubMed 33675631 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Mar 2019, 12 months.

Results were first posted in Jun 2020, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2017
First posted
Sep 29, 2017
StartActual
Mar 14, 2018
Primary completionActual
Mar 25, 2019
CompletionActual
Mar 25, 2019
Results first posted
Jun 4, 2020
Last update
Oct 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03297294
Responsible party
Sponsor
First posted
Sep 29, 2017
Start date
Mar 14, 2018
Primary completion
Mar 25, 2019
Completion
Mar 25, 2019
Results posted
Jun 4, 2020
Last update
Oct 8, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EMA400

Start the discussion